Akido has announced it is building the first AI-native health system in the US, deploying its ScopeAI technology across 100 clinics and serving 1 million patients in California, New York City, and Rhode Island. The platform organises clinical information in real time, allowing physicians to focus on patient care rather than administration. The company's revenue grew by 300% between 2024 and 2025. ScopeAI has been tested against 203,000 clinical encounters and delivers a Net Promoter Score of 96. Akido is dropping "Labs" from its name and launching Akido Medical as its clinical brand. The company has appointed Matt Rothstein as vice president of engineering and Cambron Carter as principal AI architect. It has also established an AI Clinical Advisory Council to oversee its systems.

Future Communities Institute has launched the Bay Area's first AI-powered safety net programme in partnership with Five Keys, ReImagine Freedom and Akido Labs. The initiative will use Akido's AI-enabled care model to expand street medicine teams and deliver personalised care to vulnerable populations. The programme addresses growing homelessness in the Bay Area, which has increased 6% year-over-year, with approximately two-thirds of unhoused residents living on the streets. It deploys Akido's ScopeAI system, which guides community health workers through comprehensive patient visits and can initiate medically assisted treatment for substance use disorders within four hours of initial contact. ScopeAI has been trained on over 10 million patient cases and currently supports visits across multiple medical specialties, serving 500,000 patients through Akido's network of 240 clinicians.